Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Subscribe To Our Newsletter & Stay Updated